XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.3
EQUITY AND NONCONTROLLING INTERESTS - Schedule of Earnings Per Share (Details) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 28, 2024
Sep. 30, 2023
Sep. 28, 2024
Sep. 30, 2023
Numerator:        
Net income $ 70,295 $ 88,021 $ 239,038 $ 291,418
Less: Net income attributable to noncontrolling interests 638 632 2,340 3,878
Net income attributable to Charles River Laboratories International Inc. 69,657 87,389 236,698 287,540
Calculation of net income per share attributable to Charles River Laboratories International Inc. common shareholders        
Net income attributable to Charles River Laboratories International Inc. 69,657 87,389 236,698 287,540
Less: Adjustment of redeemable noncontrolling interest 379 0 1,081 0
Less: Incremental dividends attributed to noncontrolling interest holders 599 0 9,621 0
Net income available to Charles River Laboratories International Inc. common shareholders $ 68,679 $ 87,389 $ 225,996 $ 287,540
Denominator:        
Weighted-average shares outstanding - Basic (in shares) 51,394 51,283 51,461 51,199
Effect of dilutive securities:        
Stock options, restricted stock units and performance share units (in shares) 189 324 252 294
Weighted-average shares outstanding - Diluted (in shares) 51,583 51,607 51,713 51,493
Anti-dilutive common stock equivalents (in shares) 746 588 505 514